Practice patterns of the medical evaluation of living liver donors in the United States.
Journal
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
ISSN: 1527-6473
Titre abrégé: Liver Transpl
Pays: United States
ID NLM: 100909185
Informations de publication
Date de publication:
01 02 2023
01 02 2023
Historique:
received:
01
07
2022
accepted:
02
09
2022
pubmed:
17
9
2022
medline:
25
1
2023
entrez:
16
9
2022
Statut:
ppublish
Résumé
Living donor liver transplantation (LDLT) can help address the growing organ shortage in the United States, yet little is known about the current practice patterns in the medical evaluation of living liver donors. We conducted a 131-question survey of all 53 active LDLT transplant programs in the United States to assess current LDLT practices. The response rate was 100%. Donor acceptance rate was 0.33 with an interquartile range of 0.33-0.54 across all centers. Areas of high intercenter agreement included minimum age cutoff of 18 years (73.6%) and the exclusion of those with greater than Class 1 obesity (body mass index, 30.0-34.9 m/kg 2 ) (88.4%). Diabetes mellitus was not an absolute exclusion at most centers (61.5%). Selective liver biopsies were performed for steatosis or iron overload on imaging (67.9% and 62.3%, respectively) or for elevated liver enzymes (60.4%). Steatohepatitis is considered an exclusion at most centers (84.9%). The most common hypercoagulable tests performed were factor V Leiden (FVL) (88.5%), protein C (73.1%), protein S (71.2%), antithrombin III (71.2%) and prothrombin gene mutation (65.4%). At 41.5% of centers, donors were allowed to proceed with donation with FVL heterozygote status. Most programs discontinue oral contraceptive pills at least 28 days prior to surgery. At most centers, the need for cardiovascular ischemic risk testing is based on age (73.6%) and the presence of one or more cardiac risk factors (68.0%). Defining areas of practice consensus and variation underscores the need for data generation to develop evidence-based guidance for the evaluation and risk assessment of living liver donors.
Identifiants
pubmed: 36111606
pii: 01445473-202302000-00008
doi: 10.1002/lt.26571
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
164-171Informations de copyright
Copyright © 2023 American Association for the Study of Liver Diseases.
Références
Abu‐Gazala S, Olthoff KM. Current status of living donor liver transplantation in the United States. Annu Rev Med. 2019;70:225–38. https://doi.org/10.1146/annurev‐med‐051517‐125454
doi: 10.1146/annurev-med-051517-125454
Rela M, Rammohan A. Why are there so many liver transplants from living donors in Asia and so few in Europe and the US? J Hepatol. 2021;75:975–80. https://doi.org/10.1016/j.jhep.2021.05.036
doi: 10.1016/j.jhep.2021.05.036
Kwong AJ, Ebel NH, Kim WR, Lake JR, Smith JM, Schladt DP, et al. OPTN/SRTR 2020 annual data report: liver. Am J Transplant. 2022 Mar;22(Suppl 2):204–309. https://doi.org/10.1111/ajt.16978
doi: 10.1111/ajt.16978
Pomfret EA, Lodge JP, Villamil FG, Siegler M. Should we use living donor grafts for patients with hepatocellular carcinoma? Ethical considerations. Liver Transpl. 2011 Oct;17(Suppl 2):S128–32. https://doi.org/10.1002/lt.22356
doi: 10.1002/lt.22356
Miller CM. Ethical dimensions of living donation: experience with living liver donation. Transplant Rev (Orlando). 2008 Jul;22(3):206–9. https://doi.org/10.1016/j.trre.2008.02.001
doi: 10.1016/j.trre.2008.02.001
Barr ML, Belghiti J, Villamil FG, Pomfret EA, Sutherland DS, Gruessner RW, et al. A report of the Vancouver Forum on the care of the live organ donor: lung, liver, pancreas, and intestine data and medical guidelines. Transplantation. 2006 May 27;81(10):1373–85. https://doi.org/10.1097/01.tp.0000216825.56841.cd
doi: 10.1097/01.tp.0000216825.56841.cd
Medical Evaluation, Informed Consent, and Follow‐up of the Living Liver Donor – a Consensus Document from the AST/ASTS/NATCO/UNOS Joint Societies Work Group. [cited 2021 April 1]. Available from: https://asts.org/docs/default‐source/optn‐unos/pubcmts_jswgl_recommendations_medeval_informedconsent_followup_living_liver_donor.pdf
OPTN (Organ Procurement and Transplantation Network)/UNOS (United Network for Organ Sharing). OPTN Policies, Policy 14.4: Medical Evaluation Requirements for Living Donors. [cited 2021 April 1]. Available from: https://optn.transplant.hrsa.gov/media/eavh5bf3/optn_policies.pdf
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata‐driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377–81. https://doi.org/10.1016/j.jbi.2008.08.010
doi: 10.1016/j.jbi.2008.08.010
OPTN. Organ Procurement and Transplantation Network ‐ National Data. [cited 2021 April 1]. Available from: https://optn.transplant.hrsa.gov/data/view‐data‐reports/national‐data/
AST. Living Liver Donor Provider Toolkit. 2022. [cited 2022 May 1]. Available from: https://www.myast.org/education/specialty‐resources/living‐donor‐provider‐toolkits
Trotter JF, Wisniewski KA, Terrault NA, Everhart JE, Kinkhabwala M, Weinrieb RM, et al. Outcomes of donor evaluation in adult‐to‐adult living donor liver transplantation. Hepatology. 2007 Nov;46(5):1476–84. https://doi.org/10.1002/hep.21845
doi: 10.1002/hep.21845
Kasiske BL, Ahn YS, Conboy M, Dew MA, Folken C, Levan ML, et al. Outcomes of living liver donor candidate evaluations in the Living Donor Collective pilot registry. Clin Transplant. 2021 Sep;35(9):e14394. https://doi.org/10.1111/ctr.14394
doi: 10.1111/ctr.14394
Soin AS, Chaudhary RJ, Pahari H, Pomfret EA. A worldwide survey of live liver donor selection policies at 24 centers with a combined experience of 19 009 adult living donor liver transplants. Transplantation. 2019 Feb;103(2):e39–47. https://doi.org/10.1097/TP.0000000000002475
doi: 10.1097/TP.0000000000002475
Emamaullee J, Conrad C, Kim M, Goldbeck C, Kwon Y, Singh P, et al. Assessment of the global practice of living donor liver transplantation. Transpl Int. 2021 Oct;34(10):1914–27. https://doi.org/10.1111/tri.13960
doi: 10.1111/tri.13960
Trotter JF. The diminishing role of liver biopsy in living donor liver transplantation. Liver Transpl. 2018 Apr;24(4):457–8. https://doi.org/10.1002/lt.25038
doi: 10.1002/lt.25038
Aloia TA, Geerts WH, Clary BM, Day RW, Hemming AW, D'Albuquerque LC, et al. Venous thromboembolism prophylaxis in liver surgery. J Gastrointest Surg. 2016 Jan;20(1):221–9. https://doi.org/10.1007/s11605‐015‐2902‐4
doi: 10.1007/s11605-015-2902-4
Cerutti E, Stratta C, Romagnoli R, Schellino MM, Skurzak S, Rizzetto M, et al. Thromboelastogram monitoring in the perioperative period of hepatectomy for adult living liver donation. Liver Transpl. 2004 Feb;10(2):289–94. https://doi.org/10.1002/lt.20078
doi: 10.1002/lt.20078
Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003 Jun 17;107(23 Suppl 1):I9–16. https://doi.org/10.1161/01.CIR.0000078469.07362.E6
doi: 10.1161/01.CIR.0000078469.07362.E6
Ogawa H, Fujimoto Y, Yamamoto K, Hata T, Nagai S, Kamei H, et al. Donor screening algorithm for exclusion of thrombophilia during evaluation of living donor liver transplantation. Clin Transplant. 2011 Mar–Apr;25(2):277–82. https://doi.org/10.1111/j.1399‐0012.2010.01216.x
doi: 10.1111/j.1399-0012.2010.01216.x
Kamei H, Onishi Y, Kurata N, Ishigami M, Ogura Y. Donor selection and prophylactic strategy for venous thromboembolic events in living donors of liver transplantation based on results of thrombophilia screening tests. Ann Transplant. 2017 Jul 4;22:409–16. https://doi.org/10.12659/aot.902791
doi: 10.12659/aot.902791
Bustelos R, Ayala R, Martinez J, Martin MA, Toledo T, Grande S, et al. Living donor liver transplantation: usefulness of hemostatic and prothrombotic screening in potential donors. Transplant Proc. 2009 Nov;41(9):3791–5. https://doi.org/10.1016/j.transproceed.2009.06.214
doi: 10.1016/j.transproceed.2009.06.214
Gill JS, Schold J, Kaplan B. Understanding risks and our responsibility to living donors. J Am Soc Nephrol. 2021 Nov;32(11):2691–3. https://doi.org/10.1681/ASN.2021081129
doi: 10.1681/ASN.2021081129